Get the Stockscreener App
1.25
1.63%
0.02
After Hours:
1.28
0.03
+2.40%
Icecure Medical Ltd stock is traded at $1.25, with a volume of 375.94K.
It is up +1.63% in the last 24 hours and up +13.64% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$1.23
Open:
$1.25
24h Volume:
375.94K
Relative Volume:
0.55
Market Cap:
$70.71M
Revenue:
$3.67M
Net Income/Loss:
$-13.83M
P/E Ratio:
-4.4643
EPS:
-0.28
Net Cash Flow:
$-10.79M
1W Performance:
+0.81%
1M Performance:
+13.64%
6M Performance:
+71.47%
1Y Performance:
-15.54%
1-Day Range:
$1.22
$1.2792
1-Week Range:
$1.19
$1.2799
52-Week Range:
$0.48
$1.49
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.25 | 70.71M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
128.81 | 223.42B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
103.04 | 151.86B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
390.43 | 148.84B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.99 | 117.96B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.22 | 43.19B | 6.60B | 4.16B | 490.10M | 6.93 |
Icecure Medical Ltd Stock (ICCM) Latest News
ICCMIceCure Medical Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod - MSN
IceCure submits application to China’s NMPA for cryoablation system approval - Yahoo! Voices
IceCure Medical (NASDAQ:ICCM) Stock Price Down 1.6% – Should You Sell? - Defense World
IceCure Medical Ltd. Files for Regulatory Approval of ProSense Cryoablation System in China - Marketscreener.com
IceCure Medical Seeks China Approval for Advanced ProSense Cryoablation System - StockTitan
Icecure Medical Announces Equity Distribution Agreement - TipRanks
IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025 - TipRanks
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America - Longview News-Journal
Investors bid IceCure Medical (NASDAQ:ICCM) up US$14m despite increasing losses YoY, taking five-year CAGR to 43% - Simply Wall St
The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing - Yahoo Finance
Financial Analysis: SANUWAVE Health (OTCMKTS:SNWV) versus IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule - Kilgore News Herald
IceCure Medical regains full Nasdaq compliance - Medical Buyer
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minim - GuruFocus.com
IceCure to Meet Institutional Investors at the H.C. Wainwright a - GuruFocus.com
IceCure Medical regains Nasdaq compliance - Investing.com
IceCure earns European patent win for next-gen cryoablation tech - Mass Device
IceCure Medical Ltd. Receives an Intention to Grant Notice from the European Patent Office - Marketscreener.com
Icecure Nicks Up On European OK For Connector - MENAFN.COM
IceCure Nicks Up on European OK for Connector - Baystreet.ca
European Patent Office Issues Intention to Grant Notice to IceCu - GuruFocus.com
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology - Marketscreener.com
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference - GuruFocus.com
IceCure Medical appoints new board director - Investing.com India
IceCure Medical appoints new board director By Investing.com - Investing.com Australia
Icecure Medical Appoints New Board Director with Financial Expertise - TipRanks
IceCure Medical Ltd Appoints Li Haixiang as Director - Marketscreener.com
IceCure Medical (NASDAQ:ICCM) Stock Price Down 0.4%Here's Why - MarketBeat
IceCure Medical (NASDAQ:ICCM) Shares Down 0.4% – What’s Next? - Defense World
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - Marketscreener.com
IceCure Medical's ProSense Shows Breakthrough 5-Year Breast Cancer Treatment Results in Major Clinical Trial - StockTitan
Study Published in the British Journal of Radiology Demonstrates - GuruFocus.com
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Eastern Progress Online
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - The Eastern Progress Online
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - Kilgore News Herald
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery - The Eastern Progress Online
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Eastern Progress Online
Icecure Medical (XTAE:ICCM) 9-Day RSI : N/A (As of Dec. 05, 2024) - GuruFocus.com
ICCM (Icecure Medical) EBITDA : $-14.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
IceCure's ProSense® Cryoablation Safe and Effective in Destructi - GuruFocus.com
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results - WV News
IceCure Medical Ltd (NASDAQ:ICCM) Q3 2024 Earnings Call Transcript - MSN
H.C. Wainwright reiterates Buy on IceCure Medical stock, FDA decision on ProSense expected soon - Investing.com
HC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
IceCure Medical’s sales grow 36% in nine months of 2024 - Medical Buyer
IceCure Receives Notice of Allowance from U.S. Patent and Tradem - GuruFocus.com
IceCure Medical Sees Strong Growth Amid ProSense® Adoption - TipRanks
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates - MSN
. By Investing.com - Investing.com
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):